Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Advanced Breast Cancer 1 Adenocarcinoma of the Prostate 1

Interventions

Fulvestrant 5 Letrozole 4 Capecitabine 3 pyrotinib 2 Paclitaxel 2 Goserelin 2 Anastrozole 2 palbociclib 1 olaparib 1 neratinib 1 liposomal doxorubicin 1 exemestane 1 entinostat 1 ceralasertib 1 capivasertib 1 Vinorelbine 1 Trastuzumab 1 Standard of Care 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Injections 1 In Situ Hybridization, Fluorescence 1 Immunotherapy, Adoptive 1 Gonadotropin-Releasing Hormone 1 FCN-437c 1 Docetaxel 1 Decitabine 1 Cyclophosphamide 1 Combined Modality Therapy 1 Cisplatin 1 CYH33 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Advanced Breast Cancer × capivasertib × Clear all

NCT03182634 2019-01-22

plasmaMATCH

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡